Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 5/20 | 0.40 |
| ▸ | FNTB | P49356 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128690 | 0.82 | GRIA2 (0.54) | RXFP1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL5731532 | 0.81 | GRIA4 (0.53) | ALDH1A1KDM4EMAPTKMT2ALMNA | |
| SCHEMBL3131470 | 0.81 | L3MBTL1 (0.52) | L3MBTL1RXFP1ALDH1A1KDM4EMAPT | |
| SCHEMBL623720 | 0.81 | L3MBTL1 (0.52) | L3MBTL1RXFP1ALDH1A1KDM4EMAPT | |
| SCHEMBL10288612 | 0.80 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL1552287 | 0.80 | GRIA2 (0.43) | L3MBTL1ALDH1A1GRIA2GRIA4GAA | |
| SCHEMBL3134049 | 0.79 | APOBEC3G (0.51) | L3MBTL1RXFP1ALDH1A1KDM4EMAPT | |
| SCHEMBL2680927 | 0.79 | GRIA2 (0.56) | L3MBTL1RXFP1ALDH1A1KDM4EMAPT | |
| SCHEMBL3128688 | 0.78 | L3MBTL1 (0.50) | L3MBTL1RXFP1ALDH1A1KDM4EMAPT | |
| SCHEMBL622624 | 0.78 | L3MBTL1 (0.68) | L3MBTL1RXFP1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-8796268-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796268-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1706395-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075951-A1 | Heteroaryls and uses thereof | PIK3R3, AKT1S1, PIK3R1 | L3MBTL1 2898/4885RXFP1 1040/4885ALDH1A1 1931/4885 |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | L3MBTL1 466/4885RXFP1 2451/4885ALDH1A1 429/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | L3MBTL1 3910/4885RXFP1 4836/4885ALDH1A1 1344/4885 |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | L3MBTL1 651/4885RXFP1 2530/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.